• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Jeffrey S. Weber, Sandra P D'Angelo, +25 authors James Michael Larkin
  • Medicine
  • The Lancet. Oncology
  • 2015 (First Publication: 1 April 2015)
  • BACKGROUND Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors.Continue Reading
  • Suzanne L. Topalian, Mario Sznol, +18 authors F Stephen Hodi
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2014 (First Publication: 1 April 2014)
  • PURPOSE Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade canContinue Reading
  • G A Fyfe, Richard I. Fisher, Steven A Rosenberg, Mario Sznol, David R. Parkinson, Arthur C. Louie
  • Medicine
  • Journal of clinical oncology : official journal…
  • 1995 (First Publication: 1 March 1995)
  • PURPOSE To determine the efficacy and toxicity of a high-dose interleukin-2 (IL-2) regimen in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS Two hundred fifty-five assessableContinue Reading
  • Scott N. Gettinger, Leora Horn, +26 authors Julie R. Brahmer
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2015 (First Publication: 20 April 2015)
  • PURPOSE Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was activeContinue Reading